Replies to post #252023 on Biotech Values

[charlie91]

Dew, I am new here, good day to you all. Just, I wanted to know if my interpretation to GSBR-1290 results is correct. From their presentation: -

1) I see only 37 patients had taken the obesity pill, they demonstrated very poor WL after week 8. This pill is probably not going to benefit the patients any more after week 12 and will poses health risk. Patients lost 6% in 8 weeks. After the week 8 the pill didn't work well, those patients took the pill for another 4 more weeks to lose only another 0.2%.

2) Safety profile is very bad as well.

3) I think the FDA will require a proper P2 trial, longer duration and higher number of patients.

https://ir.structuretx.com/static-files/775ca535-9bd3-455e-a41a-44dea273c90d

[jbog]

As expected for the GLP1-RA drug class, leading adverse events were gastrointestinal-related and the two most common AEs were nausea and vomiting

.

This excerpt from GPCR's PR today is somewhat misleading insofar as 89% of patients in the treatment arm experienced nausea and 62% experienced vomiting

I don't see what your seeing.

[DewDiligence]

GPCR selling 9.2M* ADSs/prefunded warrants at undetermined price:

https://www.globenewswire.com/news-release/2024/06/03/2892593/0/en/Structure-Therapeutics-Announces-Proposed-Public-Offering-of-American-Depositary-Shares-and-Pre-Funded-Warrants.html

*Assuming exercise of underwriter’s option.